First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
{{output}}
Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated dose-limiting toxicities (DLT) to define the maximum tolerated dose (MTD) and phase II recommended dose (RD) o... ...
